Specialty pharma InnoPharma was acquired by Pfizer a few years ago for up to $360 million. Now, the team behind that effort is at it again with another…

GlaxoSmithKline will pay up to £175 million ($230 million) to gain global, exclusive rights to a Phase I monoclonal antibody to treat severe asthma from…

Building on the original 2013 R&D deal between Japan’s Astellas and Cytokinetics, the two have now expanded their initial collab, which will see Astellas…

The tau theory in Alzheimer’s disease took a hit today after TauRx, one of the leading companies researching this hypothesis, saw its drug when used with…

We can rebuild him; we have the technology--but Americans question if we should in a new survey designed to assess attitudes to modern biotechnology advances.

This year will be the year of the woman exec in biotech, no doubt about it.

Kite Pharma has always been focused on engineering a patient’s own T cells to treat their cancer. But now, it’s in-licensed tech to create off-the-shelf T-cell…

Tokai had hoped that its prostate cancer candidate could best Medivation’s Xtandi, but now the microcap biotech has instead discontinued that Phase III pivotal…